African trypanosomiasis
| African trypanosomiasis | |
|---|---|
| Other names | Sleeping sickness, African sleeping sickness |
| Trypanosoma forms in a blood smear | |
| Specialty | Infectious disease |
| Symptoms | Stage 1: Fever, headache, itchiness, joint pain Stage 2: Insomnia, confusion, ataxia |
| Complications | Multiple organ dysfunction syndrome |
| Usual onset | 1–3 weeks post exposure |
| Types | Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense |
| Causes | Trypanosoma brucei spread by tsetse flies |
| Diagnostic method | Blood smear, lumbar puncture |
| Prevention | Avoiding bite of tsetse flies, including insect repellent and pest control |
| Medication | Fexinidazole, pentamidine, suramin, melarsoprol, eflornithine, nifurtimox |
| Prognosis | Fatal without treatment |
| Frequency | 583 (2024) |
| Deaths | 3,500 (2015) |
African trypanosomiasis is an insect-borne parasitic infection of humans and other animals caused by the protozoan species Trypanosoma brucei, which is transmitted by the bite of an infected tsetse fly. Human African trypanosomiasis (HAT) is also known as sleeping sickness. Humans are infected by two subspecies of T. brucei: T. brucei gambiense is primarily transmitted between humans and causes over 92% of cases, while T. brucei rhodesiense is zoonotic, with animals such as cattle serving as reservoirs.
During the first stage of the disease, T. brucei parasites replicate in the blood and lymph, causing fever, headache, itchiness, and joint pains about one to three weeks after the bite. Weeks to months later, the parasite crosses the blood–brain barrier and the second stage begins with neurological symptoms including confusion, poor coordination, numbness, and trouble sleeping. Without treatment, African trypanosomiasis almost always results in death. Diagnosis involves detecting the parasite in a blood smear or lymph node fluid. A lumbar puncture is often needed to tell the difference between first- and second-stage disease. T. brucei gambiense causes chronic infection that can take months to years to develop symptoms, while T. brucei rhodesiense infection causes symptoms within weeks to months.
Prevention involves avoiding tsetse fly bites, for example by the use of insect repellents and protective clothing. Vector control measures, such as spraying insecticides and releasing sterilized tsetse flies in endemic areas, have significantly reduced the incidence of disease. Screening the at-risk population with blood tests for T. brucei gambiense can prevent the development of severe disease. Treatment is easier when the disease is detected early and before neurological symptoms begin. The use of pentamidine or suramin treats the first stage of T. brucei infection, but if the disease progresses to the neurological stage, dosages of eflornithine or a combination of nifurtimox and eflornithine are the preferred treatment. Fexinidazole is a more recent treatment that can be taken by mouth for either stage of T. brucei gambiense. While melarsoprol works for both types of sleeping sickness, it is typically used only for T. brucei rhodesiense, due to its serious side effects.
The disease occurs regularly in some regions of sub-Saharan Africa with the population at risk being about 70 million in 36 countries. An estimated 11,000 people are currently infected with 2,800 new infections in 2015. In 2024, there were 583 confirmed cases recorded. In 2015, it caused around 3,500 deaths, down from 34,000 in 1990. More than 80% of these cases are in the Democratic Republic of the Congo. Three major outbreaks have occurred in recent history: one from 1896 to 1906 primarily in Uganda and the Congo Basin, and two in 1920 and 1970, in several African countries. It is classified as a neglected tropical disease. Other animals, such as cows, may carry the disease and become infected in which case it is known as nagana or animal trypanosomiasis.